Medical Cannabis for Rheumatoid Arthritis — Switzerland 2026
In rheumatoid arthritis and related conditions, cannabis targets pain, sleep and stiffness — not the inflammatory core. Much cheaper for members.
In RA, Sativex improved (RCT Blake 2006) rest pain and sleep. THC:CBD preparations mainly act symptomatically — DMARDs (methotrexate, biologics) remain central. Canadian surveys (Fitzcharles 2019): 40 % cannabis use with high satisfaction. CannabisClub members: 50 CHF flat instead of 190.
What the studies show
Blake 2006 (RCT, n=58): Sativex over 5 weeks — significant reduction in rest pain, sleep and DAS28 vs placebo.
Fitzcharles 2019: 40 % of Canadian rheumatology patients use cannabis; 76 % moderate/strong pain improvement.
Preparations & dosing
Sativex® 1–8 sprays/day (2.7 mg THC + 2.5 mg CBD per spray) for pain and sleep.
Dronabinol 2.5–5 mg twice daily as cheaper alternative.
Save as a CannabisClub member
Rheumatology cannabis follow-up runs in parallel. External consult 190 CHF, member 50 CHF flat — quarterly renewals 560 CHF/year saved.
Registration free.
FAQ
Does cannabis replace methotrexate or biologics?
No. It acts on symptoms (pain, sleep, stiffness), not on disease. DMARDs and biologics remain essential to prevent joint destruction.
What does membership save?
50 CHF instead of 190 CHF per consult. Quarterly 560 CHF/year. Registration free.
Does insurance cover cannabis for rheumatism?
In resistant pain, especially when opioid sparing is documented. Art. 71a HIO agreement.
Cannabis for Rheumatoid Arthritis — Prescription Switzerland 2026 (Members 50 CHF)